New CMV vaccine candidate enters first human tests
NCT ID NCT06145178
First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This early-stage trial tests a new vaccine called SPYVLP01 designed to protect against cytomegalovirus (CMV), a common virus that can cause serious problems in newborns and people with weak immune systems. The study involves 120 healthy adults aged 18 to 50 and will check if the vaccine is safe and triggers an immune response, with or without added adjuvants (boosters). Since this is a Phase 1 trial, the main focus is on safety, not yet on proving the vaccine prevents infection.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
SPYVLP01 vaccine
What this could lead to
If successful, this could lead to a vaccine that prevents cytomegalovirus (CMV) infection, protecting vulnerable people like newborns and those with weakened immune systems.
What could go wrong
This is an early Phase 1 trial with only 120 healthy adults, so it's too soon to know if the vaccine works. The main goal is safety, not proof of effectiveness.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CYTOMEGALOVIRUS INFECTIONS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Medicines Evaluation Unit
Manchester, United Kingdom
-
Velocity Bristol
Bristol, United Kingdom